Oakworth Capital Inc. Sells 326 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 1st, 2023

Oakworth Capital Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,968 shares of the company’s stock after selling 326 shares during the quarter. Johnson & Johnson makes up 0.3% of Oakworth Capital Inc.’s holdings, making the stock its 27th largest holding. Oakworth Capital Inc.’s holdings in Johnson & Johnson were worth $3,250,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Jackson Grant Investment Advisers Inc. grew its position in shares of Johnson & Johnson by 1.8% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 14,807 shares of the company’s stock worth $2,295,000 after buying an additional 258 shares in the last quarter. V Wealth Advisors LLC boosted its position in Johnson & Johnson by 2.7% during the first quarter. V Wealth Advisors LLC now owns 11,819 shares of the company’s stock valued at $1,832,000 after purchasing an additional 308 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Johnson & Johnson by 0.9% during the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after purchasing an additional 6,836 shares in the last quarter. Jacobsen Capital Management bought a new stake in Johnson & Johnson during the first quarter valued at about $567,000. Finally, Firethorn Wealth Partners LLC boosted its position in Johnson & Johnson by 1.9% during the first quarter. Firethorn Wealth Partners LLC now owns 5,614 shares of the company’s stock valued at $918,000 after purchasing an additional 105 shares in the last quarter. Institutional investors own 67.57% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 4.0 %

Johnson & Johnson stock opened at $167.53 on Tuesday. The stock has a market capitalization of $435.37 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 2.93 and a beta of 0.55. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The business has a 50 day simple moving average of $161.97 and a 200-day simple moving average of $161.07. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The business had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the previous year, the business earned $2.59 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.76 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.84%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Raymond James raised their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a research note on Friday, July 21st. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. Stifel Nicolaus increased their price target on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Finally, TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $171.60.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.